LPWM
ALXN

Lake Point Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Lake Point Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$5K Hold
55
– – ﹤0.01% 174
2019
Q4 		$6K Buy
+55
New +$5.88K ﹤0.01% 353

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Lake Point Wealth Management's ALXN Position: Q1 2020 in Review

Lake Point Wealth Management held its Alexion Pharmaceuticals (ALXN) position steady in Q1 2020 at 55 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #174.

Lake Point Wealth Management first reported a position in ALXN in Q4 2019 and has held it in 2 quarters since. The position peaked at $6K in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Lake Point Wealth Management held 55 shares of Alexion Pharmaceuticals worth $5K as of Q1 2020.
  • Lake Point Wealth Management left its Alexion Pharmaceuticals share count unchanged in Q1 2020.
  • Alexion Pharmaceuticals made up ﹤0.01% of Lake Point Wealth Management's portfolio in Q1 2020, its #174 holding.
  • Lake Point Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Lake Point Wealth Management's Alexion Pharmaceuticals position peaked at $6K in Q4 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Lake Point Wealth Management's 13F filing for Q1 2020, filed 18 May 2020.